ADORA2B and breast carcinoma: For example, as we and others have shown previously, pharmacological inhibition of the adenosine receptor ADORA2B strongly inhibits breast cancer in mice [9, 27, 28], as do monoclonal antibodies directed against PTP4A1 (PRL1) [29].